The group IIA human non-pancreatic secretory phospholipase A 2 (hnp-sPLA 2 ) is one of the enzymes implied in the inflammatory process. In the course of our work on inhibitors of this enzyme we investigated the influence of rigidity of the piperazine region on the biological activity. Several modifications were explored. Various linkers, such as amide, urea, carbamate, or alkoxyphenyl were inserted between the piperazine and the lipophilic chain. Also, modification of the piperazine core to incorporate carbonyl groups was studied. In an in vitro fluorimetric assay using the human GIIA (HPLA 2 ) and porcine pancreatic GIB enzymes, compound 60a (Y = phenoxy, R = C 18 H 37 , Z = CH 2 ) had the optimal activity with an IC 50 = 30 nM on HPLA 2 . By means of molecular modelling we attempted to get informations towards comprehension of differences in activity.
Design of new potent and selective secretory phospholipase A 2 inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives 
Introduction
Phospholipases A 2 (PLA 2 ) family members are esterases that hydrolyze glycerophospholipids at the sn-2 position. The reaction products are lysophospholipids and free fatty acids. 1 Among them, arachidonic acid (AA) is metabolized by enzymes such as cyclooxygenases (Cox-1 and Cox-2) and lipo-oxygenases and lead to the formation of prostaglandins, prostacyclin, thromboxans and leukotrienes, with important roles in numerous physiological and pathophysiological processes. Moreover, lyso Platelet-Activating Factor (lyso-PAF) is acetylated by the PAF-acetyltransferase to yield PAF, another well known pro-inflammatory mediator. The superfamily of PLA 2 comprises a number of very different proteins that can be divided into five principal kinds of enzymes, the sPLA 2 s, the cPLA 2 s, the Ca 2+ -independent PLA 2 s (iPLA 2 s), and the PAF acetylhydrolases (PAF-AH), and the lysosomal PLA 2 s. Assignment of the enzymes to a certain group is based on the catalytic mechanism (His/Asp, Ser/Asp or Ser/ His/Asp hydrolase) as well as functional and structural features. 2 The sPLA 2 s are small secreted proteins (14-18 kDa) usually containing 5-8 disulfide bonds. This group of enzymes requires lM levels of Ca 2+ for catalysis. Generally sPLA 2 s show a high activity with anionic phospholipid (PL) but only the GV and GX PLA 2 s also hydrolyze phosphatidylcholine (PC) vesicles. 3 The sPLA 2 s are found in plants, 4 insects, 5, 6 molluscs, 7 reptiles 8 and mammals. 9 sPLA 2 -IB is found in large amounts in the pancreas and its principal function is the digestion of dietary lipids. 10 This enzyme was identified and cloned in other tissues such as lung, spleen, kidney and ovary, 11, 12 and it has been proposed to be involved in various physiological and pathophysiological responses such as cell proliferation, 13 cell contraction, 14, 15 lipid mediators release, 16 acute lung injury 17 and endotoxic shock. 18 The sPLA 2 s appear to play a role in several inflammatory diseases. GIIA PLA 2 is present at high concentrations in synovial fluid from patients suffering from rheumatoid arthritis. 19 sPLA 2 s are involved in adult respiratory stress syndrome (ARDS), inflammatory bowel disease, pancreatitis, sepsis 20 and atherosclerosis. [21] [22] [23] Mammalian sPLA 2 s GIIA, GV, and GIID promote degranulation of mast cells, 24 possess potent anticoagulant activity, 25, 26 bactericidal properties and particularly the human GIIA, GV, GX and GXII and the murine GIIA, GIID, GIIE and GV. 27, 28 It is the GIIA that has physiologically significant bactericidal activity. The function of GIIA PLA 2 in tumorigenesis is a controversial issue. It is not clear if this enzyme serves as a tumour suppressor or tumour promotor. 29 In a previous paper, starting from our lead compound I 30, 31 ( Fig. 1) , we designed and synthesized piperazinic derivatives II and III 32 which were specific group II versus group I sPLA 2 2 , while inactive at 100 lM, the highest concentration used, on group I PLA 2 in an in vitro enzymatic assay. In addition, as compound I was active in the carrageenan-induced oedema model when ip administrated, but inactive per os because of its high lipophilicity (log P = 7), compound III was active either by ip or per os routes, probably for its ability to get protonated at physiological pH, leading to a better bioavailability.
In this last series, the activity appeared to be enhanced by rigidifying the piperazinic ring either by introduction of the carbonyl or branching directly the phenyl to the nitrogen as compared to a methylene linker between piperazine and phenyle. 32 Here we report a SAR study by examining the influence of structural modifications of II and III on inhibiting activity and selectivity towards GIIA versus GIB sPLA 2 s. They included replacing either one nitrogen or both by different functions as amide, carbamate, urea and/ or branching directly an alkyloxyphenyl group, keeping a long C 10 -C 18 alkyl chain. We also diminished flexibility of piperazine ring by branching one (or two) methyl group(s) on one (or two) carbon atom(s) of this cycle or replacing one (or two) methylene(s) by one (or two) carbonyl(s) leading to substituted piperazinones and piperazinediones. All of these derivatives were evaluated in our enzymatic assay for their inhibitory potency towards GIB and GIIA sPLA 2 s. This SAR was completed by a molecular modelling study to explain the observed results.
Chemistry
To ovoid the N,N 0 -disubstitution, N-monosubstituted piperazines were prepared as depicted in Scheme 1 either in two steps starting from diphenylmethylpiperazine 33 or by using an excess of piperazine. 32 Diphenylmethylpiperazine was treated with the appropriate acid chloride to give the 4-acyl-1-diphenylmethylpiperazines 1b,d which were deprotected by hydrogenolysis into the 1-acylpiperazines 2b,d. The carbamates 4a,c were obtained after preparing first the carbonates 3a,c by esterification of the corresponding primary alcohol by phenyl chloroformate followed by treatment with an excess of piperazine. In the same manner, introduction of the urea function was obtained by addition of an excess of piperazine to the chosen alkylisocyanate to give 5a,c. As for alkylpiperazines 6a,c, 7a and 8a, they were prepared as described by Boukli et al. 32 starting from the corresponding 1-alkylbromide and either piperazine or mono or dimethyl piperazines. The introduction of an alkyloxyphenyl group was achieved as outlined in Scheme 1 by O-alkylation of the commercially available 1-acetyl-4-(4-hydroxyphenyl)piperazine. This one was condensed on the corresponding alkylbromide by means of its sodium salt obtained with sodium hydride, leading to 9a,c,e. De-acetylation was performed using hydrogen chloride and afforded N-alkyloxyphenylpiperazines 10a,c,e as hydrochlorides.
The preparation of N-monosubstituted piperazinones (15a,c, 16a,c, 17b,d) and piperazinediones (18a,c, 21c) was performed following synthetic strategies depicted in Scheme 2. N-(2,2-Diethoxyethyl)benzylamine was alkylated with the appropriate alkyl bromide leading to N-alkyl-N-(2,2-diethoxyethyl)benzylamines 11a,c, followed by hydrogenolysis in the presence of catalytic palladium. Using reported procedures 34, 35 with managed modifications, condensation of these N-alkyl-2,2-diethoxyethylamines 12a,c with benzyloxycarbonylaminoacetic acid, in the presence of DCC and HOBt, allowed to obtain the corresponding carbamic acid benzyl esters 13a,c which were cyclized into 1,4-disubstituted 3,4-dihydro-2H-pyrazin-2-ones 14a,c in the presence of p-TsOH. Subsequent catalytic hydrogenolysis in acidic conditions led to 1-alkylpiperazin-2-ones 15a,c as hydrochlorides. Commercially available piperazin-2-one was treated with alkyl bromide 36 and acyl chloride to give 4-alkylpiperazin-2-ones 16a,c and 4-acylpiperazin-2-ones 17b,d, respectively. N-Chloroacetyl glycine ethyl ester was treated with the appropriate alkyl amine, then subsequent cyclization into 1-alkylpiperazine-2,5-diones 18a,c occured under heating in DMSO. 37 N-(2,2-Diethoxyethyl)oxamic acid ethyl ester was prepared from oxalic acid diethyl ester and 2,2-diethoxyethylamine according to a described procedure. 38 Treatment with tetradecylamine under reflux in ethanol then, cyclization of the so obtained N-(2,2-diethoxyethyl)-N 0 -tetradecyl oxalamide 19c using concentrated hydrochloric acid, 39 led to 1-tetradecyl-1,4-dihydropyrazine-2,3-dione 20c which was hydrogenated into 1-tetradecyl piperazine-2,3-dione 21c in the presence of palladium. The key intermediates to oxadiazolone formation are the nitrile function. Depending on the case, this was either achieved through preparation of chloride intermediates or required synthesis of activated reactants as outline in Scheme 3. Therefore chloride intermediates 22-27 were obtained by acylation of the monosubstituted 2b,d, 4a,c, 5a,c, 10a,c,e, disubstituted 7a and trisubstituted 8a piperazines using 4-chloromethylbenzoyl chloride at low temperature (0°C) to avoid reaction on the chloromethyl moiety as described previously, 23 nucleophilic substitution of the chloride atom by sodium cyanide 40 providing the nitriles 28-31, 33, 34
(Z = -CO-). Action of 4-bromomethylphenylacetonitrile which was prepared according to the previously published procedure 23 on 10a,c gave their corresponding cyanide 32a,c derivatives. At last, activation of 4-aminophenylacetonitrile was performed using 2,2,2-trichloroethylchloroformate leading to the carbamate 35.
In the piperazinone and piperazine dione series, the syntheses of the nitrile precursors of oxadiazolone moiety, substituted 
-OCO5a,c; -NHCO10a,c,e; -OPh- 41 Using 4-chloromethylbenzoyl chloride, the 1-alkylpiperazin-2-one hydrochlorides 15a,c were acylated. The chloro atom of the 1-alkyl-4-(4-chloromethylbenzoyl)piperazin-2-one intermediates 37a,c was substituted by sodium cyanide in DMSO, 42 leading to 1-alkyl-4-(4-cyanomethylbenzoyl)piperazin-2-ones 38a,c. In a same manner, 1-alkylpiperazin-3-ones 16a,c, 1-acylpiperazin-3-one 17b,d, 1-alkylpiperazine-2,5-dione 18a,c and 1-tetradecylpiperazine-2,3-dione 21c were deprotonated by sodium hydride and alkylated 36 with (4-bromomethyl)benzonitrile to give 1-alkyl-4-(4-cyanobenzyl)piperazin-3-ones 39a,c, 1-acyl-4-(4-cyanobenzyl)-piperazin-3-ones 40b,d, 1-alkyl-4-(4-cyanobenzyl) piperazine-2,5-diones 41a,c and 4-(4-cyanobenzyl)-1-tetradecylpiperazine-2,3-dione 42c, respectively. All cyano derivatives 28-36 and 38-42 were transformed into the amidoximes 43-56 by aqueous hydroxylamine. 43 The oxadiazolone derivatives 57-70 were then obtained after treatment with phenyl chloroformate according to Kohara et al. 44 adapted to our use, followed by cyclization in refluxing toluene of the crude carbonate intermediates (Scheme 5). Compounds 71 and 72 (Z = -CO-NH-) were obtained by reacting 64 with the mono substituted piperazines 5a,c and 6a,c, respectively.
Results and discussion
All the synthesized compounds were evaluated as sPLA 2 inhibitors in in vitro enzymatic tests using either human PLA 2 GIIA (HPLA 2 ) or porcine pancreatic PLA 2 GIB (PPLA 2 ) (see biological section) and the results are reported in Tables 1 and 2 . The log P values were calculated using the Rekker's hydrophobic fragmental constants method. 49 Our previous work 32 showed that introduction of a piperazine ring (compound II) in the structure of compound I did not affect neither the inhibitory effect against GIIA sPLA 2 with IC 50 of 2.2 and 3.4 lM, respectively, nor the selectivity GIIA/GIB (Table 1 ). In addition, it offered the ability of protonation at physiological pH then lowering the lipophilicity supposed to enhance biodistribution. It appeared also that rigidifying the piperazine ring by replacing Z = CH 2 , compound II, by Z = CO, compound III, with IC 50 of 2.2 and 0.8 lM, respectively, permitted to reach the value of Lilly ref-
45 (IC 50 = 0.47 lM), measured in the same conditions as ours.
Starting with these results we undertook in one hand to rigidify more the piperazine ring from the outside by replacing its two nitrogens by different functions as amide, carbamate and urea or branching a phenyl group directly on one of the nitrogens (Table  1) . In another hand, the piperazine ring was also rendered less flexible from the inside by substitution with one or two methyl groups or introducing carbonyl groups in the place of one or two methylenes (Table 2) .
At the first glance, results reported in Tables 1 and 2 show that all the synthesized compounds are active on HPLA 2 with a very high selectivity for this group II enzyme versus GIB. Comparing the global lipophilicity of the molecules calculated using Rekker's hydrophobic fragmental constants, 49 it appears that the best results are obtained with log P P 7 as found for our initial leader compound I with the advantage that, in some of them, the amine function of the piperazine allows protonation, then lowering the calculated lipophilicity of the free base (compounds 60, 61, 62, 63, 65, 67, 68 and 71) by about three log P units. Table 1 shows that replacing the first methylene group of the alkyl chain of III by a carbonyl as in 57b divides the activity by two as shown by the IC 50 of 0.8 and 1.6 lM, respectively. A better result was obtained with Y = OCO to reach a 10 times more active compound (58a, IC 50 = 0.15 lM) and 5 times with Y = NHCO in 59a (IC 50 = 0.33 lM). It is relevant noting here that 57b, 58a and 59a being isolipophilic, the difference cannot involve lipophilic interactions but appears as a consequence of the modified functional groups introduced. One could hypothesize that an unfavourable effect of the C@O in the amide 57b could be compensated by the oxygen in the carbamate 58a or the NH in the urea 59a as the ability of a hydrogen bonding in the catalytic site.
Rigidification outside the piperazine ring
A very good result is also obtained by intercaling a phenoxy moiety between the nitrogen and the alkyl chain as shown by comparing 60a and II (0.03 and 2.2 lM, respectively) in one hand, 61a and III (0.07 and 0.8 lM, respectively) leading to at least a ten times gain in activity.
The same advantage is reached by replacing one of the amine functions of II by an ureide in compound 71a (IC 50 = 0.05 lM) or both, as in 72a (IC 50 = 0.29 lM). Table 2 shows that substituting one of the methylenes of the piperazine with a methyl group (compound 62a) or two b Determined with three or more independent sample preparations using the fluorimetric binding assay and given as mean value with SD less than 20% of the mean value.
Variation inside the piperazine

Table 2
Inhibition of the enzymatic activity of human PLA 2 (GIIA) HPLA 2 and porcine pancreatic PLA 2 (GIB) PPLA 2 by piperazinone/piperazinedione derivatives of compound I, using the fluorimetric assay Determined with three or more independent sample preparations using the fluorimetric binding assay and given as mean value with SD less than 20% of the mean value. * Not determined.
(compound 63a) has few effect on the activity, compounds 62a, 63a and III bearing IC 50 of the same range, 0.58, 0.23 and 0.8 lM,
respectively. In the other hand, replacing a methylene of the piperazine by a carbonyl beside the alkyl chain decreases the activity, compound 66a (IC 50 = 1.7 lM) being half time less active as III and this result could be compared to the lost of activity between III and 57b. Introduction of a carbonyl in the piperazinic ring was attempted to obtain more or less flexible compounds but it was dependent on the success of the synthesis for this series. For example, we could not assess through our synthesis, compounds bearing carbonyls in the piperazine as in 67-70, with Z = CO and n different from zero. Lacking with these two spacers is, with our experience, 30 ,31 very unfavourable to activity as shown by comparing the IC 50 of III (Z = CO, n = 1, IC 50 = 0.8 lM), II (Z = CH 2 , n = 1, IC 50 = 2.2 lM) and IV (Z = CH 2 , n = 0, IC 50 = 5.08 lM) in one hand, and those of 66c (10 lM) and 65c (30 lM) in the other hand. Nevertheless when the CO group is close to the oxadiazolone bearing moiety, compounds more or less active as III were obtained as
shown by the IC 50 of 67a (0.97 lM) and 69a (1.3 lM), then from four to five times more active than IV, in spite of their lower lipophilicity.
As it appeared that lipophilicity was not concerned in this series, we wondered if other interactions could be involved to explain these results either intramolecular or in relation with the active site. That is the reason why some of them were selected to be studied through molecular modelling.
First, the geometries of the molecules were optimized for all the degrees of freedom at the ab initio RHF level using the double f basis set 6-31G. 46 For several compounds, an additional conformational analysis was performed as for 61 and reoptimization of the local minima thus trapped. All the calculations were performed using the GAUSSIAN software. 47 For all the studied molecules, the alkyl appendage was limited to a propyl substituent.
Optimization of the geometries shows that most of the compounds (compounds III, 57, 58, 59, 61, 63 and 66) with Z = CO and n = 1 have nearly the same profile as illustrated in Figure 2 (completed in Supplementary data) with the same 'up' orientation of the oxadiazolone ring with regard to the rest of the molecule. In 57, 58 and 59, the carbonyl on each site of the piperazine nitrogens fixes the rigid geometry due to the amide function. This feature also appears with one carbonyl in III, 61, 63 and 66. The conformational analysis of the 61 molecule allows locating four conformers with a very similar relative energy (see Supplementary data). In return, when Z = CH 2 , n = 0 (compounds IV, 67, 68, 69 and 70), the oxadiazolone moiety adopts a very different 'down' position which could explain the less activity of these molecules (Fig. 3) . The ureas 71 and 72, as for them, appear in a third type privileged conformation as a consequence of the lengthening between the piperazine and the phenyl rings, which seems favourable, as shown by their activity (Fig. 4) .
The electrostatic potential was computed at the same level as the geometry optimization. The 3D envelope is drawn at À20 kcal/mol level. All the maps show a strong electrostatic potential at the level of the oxadiazolone and several others depending of the functional groups introduced to rigidify the piperazine ring.
The characteristic potential appears in the amide region for Z = CO in 57, 61, 63 and III (Fig. 5) . In compounds bearing another carbonyl in the Y region, outside (57, 58, 59) or inside (66) another important electrostatic potential appears when compared to III which could moderate the activity depending on other factors as hydrogen bonding abilities evoked previously (Fig. 6) . It is to note that a similar electrostatic profile is shown in 69 with the two carbonyls inside the piperazine ring leading to comparable IC 50 . In another hand, those two negative wells joint together in 70 (Fig. 7) could explain the poor activity of this last.
For 60 and the compounds where Z = CH 2 (IV, 65), the nitrogen character becomes sp 3 and their lone pairs generate their own isocontour depending on the geometry.
Conclusions
We have shown that in the oxadiazolone series of PLA 2 GIIA inhibitors, rigidifying the molecules by means of a piperazine ring whose flexibility and conformation can be modulated through different functional groups could enhance the activity. The best compounds here were those bearing a phenoxy group directly attached to the nitrogen of the piperazine. The advantage is to keep the protonation ability of the nitrogen, useful for bioavailability. The introduction of carbonyls not only suppressed this protonation, but also generated an electronic character which seems unfavourable to the inhibitory effect.
Experimental
Chemistry
All materials were obtained from commercial suppliers and used without further purification. Thin layer chromatography was performed on TLC plastic sheets of Silica Gel 60F254 (layer thickness 0.2 mm) from Merck. Column chromatography purification was carried out on silica gel 60 (70-230 mesh ASTM, Merck). All melting points were determined on a digital melting point apparatus (electrothermal) and are uncorrected. The structure of all compounds was confirmed by IR and NMR spectra. IR spectra were obtained in paraffin oil with an ATI Mattson Genesis Series C NMR spectra were recorded at 200 MHz and 50 MHz, respectively, in CDCl 3 or otherwise specified, on a BRUKER AC 200 spectrometer using hexamethyldisiloxane (HMDS) as an internal standard. Chemical shifts are given in ppm and peak multiplicities are described as follows: s, singlet, ls, large singlet, d, doublet, t, triplet, m, multiplet. Elemental analyses were obtained from the 'Service Régional de Microanalyse' (Université Pierre et Marie Curie, Paris, France) and were within ± 0.4% of theoretical values.
In vitro biological activity assay
PLA 2 activity was evaluated by the method of Radvanyi et al. 48 Enzymes used were two secretory enzymes: human recombinant PLA 2 of group II, HPLA 2 (GIIA) and porcine pancreatic PLA 2 of group I, PPLA 2 (GIB). Palmitoyl-2-(10-pyrenyldecanoyl)-sn-glycero-3- phosphatidyl glycerolic acid was used as a fluorescent substrate in the fluorometric assay which was performed with a Perkin-Elmer LS50 luminescence spectrometer in a unit dosage polystyrene cell having a size of 1 cm. The concentration of the fluorescent substrate was determined by UV Unicam spectrometry in a quartz cell. The experimental protocol was the same as described in our previous publications.
30-32
4-Diphenylmethyl-1-octadecanoylpiperazine (1b)
A solution of N-diphenylmethyl piperazine (20 g, 79 mmol) in Et 3 N (12 mL, 120 mmol) and dry toluene (200 mL) was cooled in an ice bath. Octadecanoyl chloride (26.4 g, 100 mmol) solubilized in dry toluene (150 mL) was added dropwise and the mixture was stirred at 0°C for 1 h. The organic layer was washed with a 
1-Octadecanoylpiperazine (2b)
To a solution of the amide 1b (24 g, 69 mmol) in EtOH (150 mL) was added 100 mg Pd-C, and this mixture was warmed (50°C) with stirring under hydrogen atmosphere. After disappearance of the starting material (12 h) as shown by TLC, the suspension was filtered and the catalyst washed several times with EtOH. The solvents were evaporated and the residue chromatographed on a silica gel column using CH 2 Cl 2 as eluent to yield 10 g (72.5%) of 2b as a yellow powder: mp 98°C; R f 0.25 (CH 2 
Octadecylphenylcarbonate (3a)
A solution of 1-octadecanol (10 g, 37 mmol) in Et 3 N (6.25 mL, 44 mmol) and freshly distilled THF (80 mL) was cooled in an ice bath. A solution of phenyl chloroformate (5.63 mL, 44 mmol) in THF (30 mL) was added dropwise and the mixture was stirred at 0°C for 1 h. The solvent was evaporated and the residue, taken up in CH 2 Cl 2 , was washed with a saturated Na 2 CO 3 solution and twice with water. After drying (MgSO 4 ), filtration and evaporation, the residue was chromatographed on a silica gel column using CH 2 Cl 2 as eluent to yield 9.42 g (66%) of carbonate 3a as an oil: 
N-Octadecyloxycarbonylpiperazine (4a)
A mixture of carbonate 3a (9.42 g, 24 mmol) and piperazine (20.77 g, 241 mmol) in 100 mL THF/CH 2 Cl 2 (3:1) was stirred at room temperature for 1 h. The solvents were evaporated; the residue was taken up in CH 2 Cl 2 and washed twice with water. The organic phase was then dried over MgSO 4 , filtered and concentrated in vacuo. The product was crystallized in acetone to yield 4. 
N-Octadecylaminocarbonylpiperazine (5a)
A mixture of octadecyl isocyanate (4.42 g, 15 mmol) and piperazine (13 g, 151 mmol) in CH 2 Cl 2 (70 mL) was stirred at room temperature for 1 h. The solution was washed twice with water. The organic phase was then dried over MgSO 4 
1-Acetyl-4-(4-octadecyloxyphenyl)piperazine (9a)
To a solution of 1-acetyl-4-(4-hydroxyphenyl)piperazine (2.36 g, 0.059 mol) in DMF (100 mL) was added dropwise a suspension of NaH (60% dispersion in mineral oil, 10.8 g, 0.049 mol) in DMF (30 mL). The mixture was stirred at room temperature for 30 min and 1-bromooctadecane (13.8 g, 0.049 mol) in DMF (50 mL) was added dropwise. The resulting mixture was warmed (60°C) with stirring for 2 h. After cooling, water (100 mL) was added and the precipitated crystals were collected, washed with water and dried to provide 9a (15.57 g, 95%) which was used in the next step without purification: mp 117°C; R f 0.40 (CH 2 12 (s, 3H), 1.80-1.7 (m,  2H), 1.19 (ls, 30H) , 0.81 (t, 3H, J = 6.1 Hz).
1-(4-Octadecyloxyphenyl)piperazine dihydrochloride (10a)
A mixture of 9a (15 g, 33 mmol) in EtOH (150 mL) and 12 N HCl (30 mL) was warmed to reflux for 3 h. The solvent was evaporated under reduced pressure to give a viscous solid. The taking up in MeOH (100 mL) made precipitate crystals which were collected and dried to provide 14 g (85%) of 10a: mp 220°C; R f 0. 3 .83 (t, 2H, J = 6.5 Hz), 1.68-1.6 (m, 2H), 1.14 (ls, 30H), 0.81 (t, 3H, J = 6.1 Hz).
N-(2,2-Diethoxyethyl)-N-tetradecylbenzylamine (11c)
To a mixture of N-(2,2-diethoxyethyl)benzylamine (51.6 g, 0.23 mol), potassium carbonate (63.9 g, 0.46 mol) and potassium iodide (1 g, 6.02 mmol) in acetonitrile (700 mL) was added 1-bromotetradecane (64 g, 0.23 mol) and the reaction mixture was refluxed for 12 h. After cooling to room temperature, the mixture was filtered and evaporated under reduced pressure. The crude residue was taken up into CH 2 Cl 2 and washed with water. The organic layer was dried over MgSO 4 , then filtered and evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using CH 2 
N-(2,2-Diethoxyethyl)tetradecylamine (12c)
To a solution of 11c (88 g, 0.2 mol) in ethanol (300 mL) was added 10% Pd-C (0.5 g). The suspension was shaken vigorously under H 2 (50 PSI) and heated at 40°C for 48 h. After cooling to room temperature and filtration through a glass frit funnel covered with a layer of Celite 545, the solvent was removed under reduced pressure and the resulting residue was purified by column chromatography on silica gel using CH 2 Cl 2 to afford 12c as a colorless oil (59 g, 90%): R f 0. 
N-Tetradecyl carbamic acid benzyl ester (13c)
A mixture of 12c (53.8 g, 0.16 mol), N-carbobenzyloxyglycine (33.1 g, 0.16 mol), triethylamine (46 mL, 0.3 mol) and 1-hydroxybenzotriazole (26 g, 0.19 mol) were dissolved in dichloromethane (120 mL). The solution was stirred for 10 min then N,N 0 -dicyclohexylcarbodiimide (37 g, 0.18 mol) was added and the reaction mixture was heated to reflux for 2 h. After cooling to room temperature, the mixture was filtered. The organic layer was washed with water and brine, subsequently, then dried over MgSO 4 , and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using CH 2 5.14. 3,4-Dihydro-1-tetradecyl-2H-pyrazin-2-one (14c)
To a solution of compound 13c (23 g, 47 mmol) in toluene (250 mL) was added a catalytic amount of p-TsOH (936 mg, 4.7 mmol). After heating to 60°C for 3 h, the solution was allowed to cool to room temperature and washed with water. The organic layer was dried over MgSO 4 , filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using CH 2 Cl 2 to obtain 14c as a yellow oil 
1-Tetradecylpiperazin-2-one hydrochloride (15c)
To a solution of 14c (10.5 g, 24.6 mmol) in ethanol (100 mL) were added 10% Pd-C (1 g) and concentrated hydrochloric acid (5 mL). The suspension was shaken vigorously under H 2 (50 PSI) and heated to 40°C for 6 h. After cooling to room temperature and filtration through a glass frit funnel covered with a layer of Celite 545, the solvent was evaporated in vacuo and the resulting residue was purified by crystallization in ether to afford 15c as a yellow powder (7 g, 86%): mp 161,6°C (decomposed); R f 0. 
1-Tetradecylpiperazin-3-one (16c)
To a mixture of piperazin-2-one (1.9 g, 19 mmol) and potassium carbonate (5.25 g, 38 mmol) in DMF (20 mL) was added dropwise a solution of 1-bromotetradecane (5.28 g, 19 mmol) in DMF (20 mL). After stirring for 24 h at room temperature, water (50 mL) was added and the mixture was extracted with ether. The organic layer was washed with brine, dried over MgSO 4 , then filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using CH 2 Cl 2 /MeOH, 98:2, v/v, to give 16c as a white powder (4. 
1-Tetradecanoylpiperazin-3-one (17d)
A solution of piperazin-2-one (1 g, 10 mmol) and triethylamine (1.7 mL, 12 mmol) in dichloromethane (80 mL) was stirred for 10 min at room temperature then cooled to 0°C and tetradecanoyl chloride (3 mL, 11 mmol) was added. The reaction mixture was stirred for 12 h at room temperature, then washed with a saturated solution of NaHCO 3 and water. The organic layer was dried over MgSO 4 , filtered and concentrated under reduced pressure. The resulting residue was purified by crystallization in acetone to afford 17d as a white powder (2. 19 (m, 20H) , 0.81 (t, 3H, J = 6.39 Hz).
1-Tetradecylpiperazine-2,5-dione (18c)
A solution of N-chloroacetylglycine ethyl ester (1 g, 5.57 mmol) and 1-tetradecylamine (4.74 g, 22.3 mmol) in DMSO (58 mL) was heated at 60°C for 48 h. After cooling to room temperature, water (130 mL) was added and the mixture was extracted three times with ether. The organic layer was dried over MgSO 4 , filtered and evaporated under reduced pressure. The crude residue was purified by silica gel column chromatography using CH 2 
A solution of N-(2,2-diethoxyethyl)oxamate ethyl ester (16.33 g, 70 mmol) and 1-tetradecylamine (14.9 g, 70 mmol) in ethanol (250 mL) was stirred under argon atmosphere and heated to reflux for 6 h. After cooling to room temperature, the mixture was filtered and the resulting solid was purified by crystallization in ethanol to afford 19c as a yellow powder (21. 
1-Tetradecylpiperazine-2,3-dione (21c)
To a suspension of 20c (6 g, 19.5 mmol) in ethyl acetate (300 mL) was added 10% Pd-C (1 g). The mixture was shaken vigorously under H 2 (50 PSI) and heated to 40-60°C for 48 h. After cooling to room temperature and filtration through a glass frit funnel covered with a layer of Celite 545, the solvent was evaporated in vacuo and the resulting yellow solid 21c was used without further purification: mp 101°C (decomposed); R f 0. 
1-(4-Chloromethylbenzoyl)-4-octadecanoylpiperazine (22b)
A mixture of 1-octa decanoylpiperazine 2b (3.28 g, 9.3 mmol) and Et 3 N (1.41 mL, 14 mmol) in CH 2 Cl 2 (50 mL) was stirred at 0°C for 10 min. A solution of 4-(chloromethyl)benzoyl chloride (2.11 g, 11.16 mmol) in CH 2 Cl 2 (25 mL) was added dropwise and the mixture was stirred at room temperature for 2 h. The solution was washed with a saturated Na 2 CO 3 solution and twice with water. After drying (MgSO 4 ), filtration and evaporation, the residue was chromatographed on a silica gel column using CH 2 Cl 2 as eluent to yield 3.47 g (79%) of 22b as white crystals: mp 53°C; R f 0. 
1-(4-Cyanomethylbenzyl)-4-(4-octadecyloxyphenyl) piperazine (32a)
A mixture of 10a (3.28 g, 7 mmol), 4-bromomethylphenylacetonitrile 23 A solution of 1-tetradecylpiperazin-2-one hydrochloride 15c, hydrochloride (6 g, 18 mmol) and triethylamine (7.6 mL, 54 mmol) in benzene (140 mL) was cooled to 0°C and a solution of 4-chloromethylbenzoyl chloride (4.1 g, 21.6 mmol) in benzene (20 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The solvent was removed in vacuo. The remaining residue was taken up in CH 2 Cl 2 and washed with a saturated Na 2 CO 3 solution then with water. The organic layer was dried over MgSO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography using CH 2 
1-(4-Cyanomethylbenzoyl)-1-tetradecylpiperazin-2-one (38c)
The intermediate 37c (4.3 g, 9.6 mmol) was dissolved in DMSO (67 mL) and the solution was cooled to 0°C. Sodium cyanide (1.87 g, 38.3 mmol) was added in small portions and the reaction mixture was heated to 50-55°C for 2 h. After cooling to room temperature, water was added and the solution was extracted with CH 2 Cl 2 . The organic layer was dried over MgSO 4 , filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using CH 2 
1-(4-Cyanobenzyl)-4-tetradecylpiperazin-2-one (39c)
Sodium hydride (60% dispersion in oil, 560 mg, 14 mmol) was added to a stirred solution of 1-tetradecylpiperazin-3-one 16c (3.47 g, 11.68 mmol) in freshly distilled THF (50 mL). The mixture was stirred for 1 h at room temperature under argon atmosphere and a solution of p-cyanobenzyle bromide (2.97 g, 15.2 mmol) in THF (10 mL) was added dropwise at 0°C. After stirring for 30 min, the reaction mixture was allowed to warm to room temperature and stirred for 18 h. MeOH (2 mL) was added and the solvent was removed in vacuo. The resulting residue was taken up in CH 2 Cl 2 and washed with water. The organic layer was dried over MgSO 4 , filtered and evaporated under reduced pressure. The crude residue was purified by silica gel column chromatography using CH 2 41 (m, 2H), 1.19 (m, 22H) , 0.81 (t, 3H, J = 6.33 Hz).
1-(4-N-Hydroxyamidinomethylbenzoyl)-4-octadecanoylpiperazine (43b)
To a solution of 28b (2 g, 4 mmol) in ethanol (50 mL) was added NH 2 OH (50% w/w solution in water, 0.47 mL, 16 mmol). After refluxing at 80°C for 5 h, concentration to dryness afforded 2.15 g (97%) of amidoxime 43b as a yellow solid in sufficient purity for use in the next step without purification: mp 128°C; R f 0. 44 Phenyl chloroformate (0.75 g, 4 mmol) was added dropwise to an ice-cooled mixture of amidoxime 43b (2.15 g, 4 mmol) and Et 3 N (0.68 g, 4.8 mmol) in dry THF (30 mL). The resulting mixture was stirred at 0°C for 1 h, the solvent was evaporated under reduced pressure and the residue, taken up in CH 2 Cl 2 , was washed with a saturated Na 2 CO 3 solution and twice with water. After drying (MgSO 4 ), filtration and evaporation, the residue was dissolved in toluene and heated under reflux for 4 h. The reaction mixture was concentrated in vacuo and the residue was chromatographed on a silica gel column using CH 2 A mixture of 64 (1.08 g, 3 mmol) and 1-octadecylpiperazine 6a 23 (1 g, 3 mmol) in acetonitrile (20 mL) was heated to reflux for 5 h. A white precipitate appeared and the hot suspension was filtered to yield 1 g of 71a (60%) as a beige powder: mp 160°C; R f 0. 
